ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF)

ClinicalTrials.gov ID: NCT01348490

Public ClinicalTrials.gov record NCT01348490. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 16, 2026, 3:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-Label Assessment of Safety and Efficacy of Ruxolitinib (INCB018424) in Subjects With Primary Myelofibrosis, Post- Essential Thrombocythemia Myelofibrosis, and Post-Polycythemia Vera Myelofibrosis Who Have Platelet Counts of 50 × 10^9/L to 100 × 10^9/L

Study identification

NCT ID
NCT01348490
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Incyte Corporation
Industry
Enrollment
66 participants

Conditions and interventions

Interventions

  • Ruxolitinib Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 14, 2011
Primary completion
Dec 18, 2018
Completion
Dec 18, 2018
Last update posted
Jan 27, 2020

2011 – 2018

United States locations

U.S. sites
38
U.S. states
23
U.S. cities
38
Facility City State ZIP Site status
Not listed Birmingham Alabama
Not listed Beverly Hills California
Not listed Burbank California
Not listed La Jolla California
Not listed Los Angeles California
Not listed Pomona California
Not listed San Diego California
Not listed New Haven Connecticut
Not listed Fort Myers Florida
Not listed Jacksonville Florida
Not listed Orange City Florida
Not listed Atlanta Georgia
Not listed Augusta Georgia
Not listed Chicago Illinois
Not listed Iowa City Iowa
Not listed Louisville Kentucky
Not listed New Orleans Louisiana
Not listed Baltimore Maryland
Not listed Ann Arbor Michigan
Not listed Southfield Michigan
Not listed St Louis Missouri
Not listed Hackensack New Jersey
Not listed Morristown New Jersey
Not listed Somerville New Jersey
Not listed New York New York
Not listed Durham North Carolina
Not listed Hickory North Carolina
Not listed Canton Ohio
Not listed Cleveland Ohio
Not listed Portland Oregon
Not listed Danville Pennsylvania
Not listed Hershey Pennsylvania
Not listed Charleston South Carolina
Not listed Nashville Tennessee
Not listed Houston Texas
Not listed San Antonio Texas
Not listed Salt Lake City Utah
Not listed Burlington Vermont

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01348490, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 27, 2020 · Synced May 16, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01348490 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →